#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Malformation venous Vitamin B12 deficiency Thrombocytopenia Acute hepatic failure Cervix carcinoma Stress cardiomyopathy Non-small cell lung cancer recurrent Obliterative bronchiolitis Turner's syndrome Alpha-1 antitrypsin deficiency Heart disease congenital Mixed-type liposarcoma Myxofibrosarcoma Endocrine ophthalmopathy Retinitis pigmentosa More trials…

    Learn about Rare Diseases

    MELAS syndrome – Trials in Disease Nephrotic syndrome Cystic fibrosis – Diagnostics Ehlers-Danlos syndrome – Basic Information Haemophilia Pleomorphic leiomyosarcoma – Treatment Leiomyosarcoma metastatic – Treatment Acute respiratory distress syndrome – Trials in Disease Breast angiosarcoma metastatic – Treatment Haemophilia B with anti factor IX – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Liraglutide Eclitasertib Sodium Gluconate Damoctocog Alfa Pegol Tertomotide Bevacizumab Zirconium Zr-89 Gindameran Interferon Alfa Sodium Chloride KETOROLAC Loncastuximab Tesirine Leflunomide Frexalimab Ddcart‐Cd19 ALN-961583 Naproxen Sodium Treprostinil Palmitil IBANDRONIC ACID Entecavir Nvl-655 More therapies…

    Learn about Your Condition

    Thrombosis Macular oedema Pancreatic fistula Follicular thyroid cancer Hyperparathyroidism secondary Synovial sarcoma Spinal cord injury Chordoma Head and neck cancer Neuroendocrine tumour Hepatic cirrhosis Partial lipodystrophy Vitiligo Lung adenocarcinoma stage III Still's disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Cystic fibrosis

  • Study on VX-522 and Ivacaftor for Adults with Cystic Fibrosis Unresponsive to CFTR Modulator Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Cystic fibrosis
    Investigated Drugs:
    • Vx-522
    • Ivacaftor
    Belgium Germany Italy The Netherlands Spain Sweden

  • Study on the Safety and Tolerance of BI 1291583 in Adults with Cystic Fibrosis Bronchiectasis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Bronchiectasis
    • Cystic fibrosis
    Investigated Drugs:
    • Bi 1291583
    • Salbutamol Sulfate
    Belgium France Germany Italy The Netherlands Spain

  • Study on the Effects of Inhaled ETD001 for People with Cystic Fibrosis

    Not recruiting

    2 1
    Investigated Diseases:
    • Cystic fibrosis
    Investigated Drugs:
    • 3-Amino-N-{[5-[4-[Bis[(2S,3R,4R,5R)-2,3,4,5,6-Pentahydroxyhexyl]Amino]Piperidine-1-Carbonyl]-1,3-Diethyl-Benzimidazol-1-Ium-2-Yl]Methyl}-5H-Pyrrolo[2,3-B]Pyrazine-2-Carboxamide Dihydrochloride Chloride
    France Germany Italy

  • Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Elexacaftor
    • Ivacaftor
    • Tezacaftor
    Austria Belgium Czechia France Germany Hungary +7

  • Study on Long-term Safety and Efficacy of Elexacaftor, Tezacaftor, and Ivacaftor for Cystic Fibrosis in Patients Aged 12 Months and Older

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Cystic fibrosis
    Investigated Drugs:
    • Elexacaftor
    • Ivacaftor
    • Tezacaftor
    Denmark Germany The Netherlands
Previous Page
1 2 3 4

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!